Skip to content

PHARMA-BIO SERV, INC.: 10-Q filed 2014-06-16

What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2014-06-16 (fiscal Q2 2014): 33 published measures, 110 facts as tagged in accession 0001354488-14-003317.

This filing

Form
10-Q (quarterly report)
Filed
2014-06-16
Fiscal period
fiscal Q2 2014
Accession
0001354488-14-003317 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-04-3021,605,962USD
At 2013-10-3121,281,936USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-04-302,530,102USD
At 2013-10-313,232,175USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-04-3019,075,860USD
At 2013-10-3118,049,761USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-04-3012,828,589USD
At 2014-01-3113,782,775USD
At 2013-10-3112,045,923USD
At 2013-04-308,493,086USD
At 2013-01-317,011,951USD
At 2012-10-316,538,113USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-02-01 to 2014-04-30327,778USD89
2013-11-01 to 2014-04-30989,711USD181
2013-02-01 to 2013-04-301,387,280USD89
2012-11-01 to 2013-04-302,440,525USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-02-01 to 2014-04-30-882,222USD89
2013-11-01 to 2014-04-30869,430USD181
2013-02-01 to 2013-04-301,519,758USD89
2012-11-01 to 2013-04-301,962,744USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-02-01 to 2014-04-3065,612USD89
2013-11-01 to 2014-04-3065,612USD181
2013-02-01 to 2013-04-3018,278USD89
2012-11-01 to 2013-04-3099,733USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-02-01 to 2014-04-30-10,294USD89
2013-11-01 to 2014-04-30-20,653USD181
2013-02-01 to 2013-04-30-9,759USD89
2012-11-01 to 2013-04-3090,537USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2014-02-01 to 2014-04-30-65,612USD89
2013-11-01 to 2014-04-30-65,612USD181
2013-02-01 to 2013-04-30-18,278USD89
2012-11-01 to 2013-04-30-99,733USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-04-3018,182,880USD
At 2013-10-3117,193,203USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-02-01 to 2014-04-3023,049,176shares89
2013-11-01 to 2014-04-3022,910,371shares181
2013-02-01 to 2013-04-3022,664,686shares89
2012-11-01 to 2013-04-3021,709,740shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-02-01 to 2014-04-3023,788,002shares89
2013-11-01 to 2014-04-3023,755,729shares181
2013-02-01 to 2013-04-3023,366,117shares89
2012-11-01 to 2013-04-3023,158,723shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-02-01 to 2014-04-300.014USD/shares89
2013-11-01 to 2014-04-300.043USD/shares181
2013-02-01 to 2013-04-300.061USD/shares89
2012-11-01 to 2013-04-300.112USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-02-01 to 2014-04-300.014USD/shares89
2013-11-01 to 2014-04-300.042USD/shares181
2013-02-01 to 2013-04-300.059USD/shares89
2012-11-01 to 2013-04-300.105USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-02-01 to 2014-04-3090,634USD89
2013-11-01 to 2014-04-30256,321USD181
2013-02-01 to 2013-04-30361,189USD89
2012-11-01 to 2013-04-30598,477USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-04-30940,584USD
At 2013-10-31976,423USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-02-01 to 2014-04-3017,100USD89
2013-11-01 to 2014-04-3034,200USD181
2013-02-01 to 2013-04-302,166USD89
2012-11-01 to 2013-04-304,332USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-02-01 to 2014-04-30419,263USD89
2013-11-01 to 2014-04-301,246,883USD181
2013-02-01 to 2013-04-301,747,714USD89
2012-11-01 to 2013-04-303,038,018USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-04-3020,648,452USD
At 2013-10-3120,288,622USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-04-302,420,254USD
At 2013-10-313,180,451USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-04-307,039,270USD
At 2013-10-317,403,987USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2014-02-01 to 2014-04-302,089,914USD89
2013-11-01 to 2014-04-304,462,115USD181
2013-02-01 to 2013-04-303,121,625USD89
2012-11-01 to 2013-04-305,688,393USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2014-02-01 to 2014-04-301,670,651USD89
2013-11-01 to 2014-04-303,215,232USD181
2013-02-01 to 2013-04-301,373,911USD89
2012-11-01 to 2013-04-302,650,375USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-04-3023,049,462shares
At 2013-10-3122,702,186shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-04-30-74,564USD
At 2013-10-31-76,752USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-04-302,067,851USD
At 2013-10-311,880,346USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-04-3016,926USD
At 2013-10-3116,891USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-02-01 to 2014-04-30418,412USD89
2013-11-01 to 2014-04-301,246,032USD181
2013-02-01 to 2013-04-301,748,469USD89
2012-11-01 to 2013-04-303,039,002USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2014-02-01 to 2014-04-30347,597USD89
2013-11-01 to 2014-04-30991,899USD181
2013-02-01 to 2013-04-301,355,828USD89
2012-11-01 to 2013-04-302,437,433USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-02-01 to 2014-04-3095,850USD89
2013-11-01 to 2014-04-30187,505USD181
2013-02-01 to 2013-04-3083,025USD89
2012-11-01 to 2013-04-30164,103USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-02-01 to 2014-04-30-851USD89
2013-11-01 to 2014-04-30-851USD181
2013-02-01 to 2013-04-30755USD89
2012-11-01 to 2013-04-30984USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-02-01 to 2014-04-300USD89
2013-11-01 to 2014-04-300USD181
2013-02-01 to 2013-04-300USD89
2012-11-01 to 2013-04-30109,859USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-02-01 to 2014-04-301,324,557USD89
2013-11-01 to 2014-04-30-407,079USD181
2013-02-01 to 2013-04-30-76,932USD89
2012-11-01 to 2013-04-30-10,239USD181

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))